Everything below concerns dual agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-27. Numbers and descriptions here follow the published literature rather than marketing material.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
固体状态的 tirzepatide 通常以冻干粉形式保存，推荐在低温、避光、干燥条件下存放，常见区间为 2 至 8 摄氏度，长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出，从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。
溶解操作一般使用注射用水或适宜的水性缓冲液，必要时加入少量助溶剂以改善溶解速度，但应避免剧烈涡旋振荡，因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态，具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分，则取决于用途是否为多次取样。
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Free base form |
| Molecular mass | Approximately 4813 Da | Calculated from the sequence |
| Amino acid residues | 39 | GIP-derived backbone |
| Receptor targets | GIP and GLP-1 | Dual agonist |
| Circulating half-life | About 5 days | Supports weekly administration |
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
== History == A 13th century manuscript by Ibn Nafis contains the earliest known description of capillaries. The manuscript records Ibn Nafis' prediction of the existence of the capillaries which he described as perceptible passages (manafidh) between pulmonary artery and pulmonary vein. These passages would later be identified by Marcello Malpighi as capillaries. He further states that the heart's two main chambers (right and left ventricles) are separate and that blood cannot pass through the (interventricular) septum. William Harvey did not explicitly predict the existence of capillaries, but he saw the need for some sort of connection between the arterial and venous systems. In 1653, he wrote, "...the blood doth enter into every member through the arteries, and does return by the veins, and that the veins are the vessels and ways by which the blood is returned to the heart itself; and that the blood in the members and extremities does pass from the arteries into the veins (either mediately by an anastomosis, or immediately through the porosities of the flesh, or both ways) as before it did in the heart and thorax out of the veins, into the arteries..." Marcello Malpighi was the first to observe directly and correctly describe capillaries, discovering them in a frog's lung 8 years later, in 1661. August Krogh discovered how capillaries provide nutrients to animal tissue. For his work he was awarded the 1920 Nobel Prize in Physiology or Medicine.
== History == Seer was founded in 2017 by Omid Farokhzad, Philip Ma, and Robert Langer, based on nanoparticle technologies developed in Farokhzad’s laboratory at Brigham and Women’s Hospital, Harvard Medical School. Early investors included Maverick Capital, aMoon Fund, Wing VC, T. Rowe Price, and Fidelity. In September 2020, Seer spun off PrognomiQ to focus on clinical applications, such as developing a liquid biopsy blood test for early lung cancer detection. Philip Ma became President and CEO of PrognomiQ. Farokhzad serves as chair of the board of directors of PrognomiQ. Seer retains approximately 19% ownership in the company. On December 4, 2020, Seer completed its initial public offering, raising approximately $336.2 million in proceeds. Underwriters included J.P. Morgan, Morgan Stanley, Bank of America Securities, and Cowen. Seer launched the Proteograph Product Suite in January 2021, which included the SP100 automation instrument and the Proteograph RISE assay kit. In June 2023, the company introduced the Proteograph XT assay kit, which increased system throughput by 150%. In May 2025, Seer released a high-throughput version of the Proteograph Product Suite, including the Proteograph ONE Assay and SP200 Automation Instrument. The system supports processing of up to 1,000 samples per week and is designed for large-scale proteomic studies.
AM404, also known as N-arachidonoylphenolamine, is an active metabolite of paracetamol (acetaminophen), responsible for all or part of its analgesic action and anticonvulsant effects. Chemically, it is the amide formed from 4-aminophenol and arachidonic acid. AM404 is one of the AM cannabinoids discovered by Alexandros Makriyannis and his team.
Sources: en.wikipedia.org
Although anabolic steroid was originally intended to specifically describe testosterone-derived steroids with a marked dissociation of anabolic and androgenic effect, it is applied today indiscriminately to all steroids with AR agonism-based anabolic effects regardless of their androgenic potency, including even non-synthetic and non-preferentially-anabolic steroids like testosterone. While many anabolic steroids have diminished androgenic potency in comparison to anabolic potency, there is no anabolic steroid that is exclusively anabolic, and hence all anabolic steroids retain some degree of androgenicity. (Likewise, all "androgens" are inherently anabolic.) Indeed, it is likely impossible to fully dissociate anabolic effects from androgenic effects, as both types of effects are mediated by the same signaling receptor, the AR. As such, the distinction between the terms anabolic steroid and androgen is questionable, and this is the basis for the revised and more recent term anabolic–androgenic steroid (AAS).
In Table 1, "Name" refers to the common name of the reference, "Material" gives its chemical formula and phase, "Type of ratio" is the isotopic ratio reported in "Isotopic ratio", "δ" is the δ value of the material with indicated reference frame, "Type" is the category of the material using the notation of Gröening (2004) (discussed below), "Citation" gives the article(s) reporting the isotopic abundances on which the isotope ratio is based, and "Notes" are notes. The reported isotopic ratios reflect the results from individual analyses of absolute mass fraction, aggregated in Meija et al. (2016) and manipulated to reach the given ratios. Error was calculated as the square root of the sum of the squares of fractional reported errors, consistent with standard error propagation, but is not propagated for ratios reached through secondary calculation.
Their data show that the most-cited think tank was the Brookings Institution, followed by the Council on Foreign Relations, the American Enterprise Institute, The Heritage Foundation, and the Center for Strategic and International Studies.
Constanza Vieira (July 16, 2010). "'Let's talk about the disappeared'". Inter Press Service. Archived from the original on July 18, 2010. "Indigenous Community in Colombia Fears Start of "Dirty War". Democracy Now!. Archived from the original on February 23, 2006. Retrieved February 24, 2006. Guests: Ezequiel Vitonas, former mayor of Toribio, and Manuel Rozental, human rights activist. Interviewers: Juan Gonzalez and Amy Goodman. Segment available in and via streaming real audio , 128k streaming Real Video or MP3 download. The Colombian Miracle Archived October 18, 2015, at the Wayback Machine
Sources: en.wikipedia.org
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.
A fatty diacid side chain promotes binding to albumin, which delays clearance from circulation. The half-life of roughly five days makes a weekly schedule practical.
No. It is a synthetic peptide whose backbone is based on the natural incretin hormone GIP. Non-natural residues and the lipid side chain were engineered to improve stability and duration of action.
建议在低温、避光、干燥环境中密封保存，常见条件为 2 至 8 摄氏度，长期存放可置于更低温度。应避免反复冻融，并尽量减少容器开启次数。